NFE2L2 and hepatocellular carcinoma: Indeed, specific inhibitors targeting the interaction between P-p62 and Keap1, opposing tumor cells proliferation and chemoresistance have been proposed as treatment for HCC, and could be exploited also in other tumor types featuring NRF2 hyperactivation [145,146].